Exforge Deal 'More Pernicious' Than Actavis, Court Told

By Bryan Koenig ( November 8, 2018, 6:03 PM EST) -- An alleged deal between Novartis and Par Pharmaceutical to delay a generic of hypertension medication Exforge is illegal because it was far more anticompetitive than what the U. S. Supreme Court dealt with in its landmark Actavis decision, Walgreens and Kroger told a New York federal court Wednesday. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Law360 is pleased to announce the Rising Stars of 2025, our list of more than 150 attorneys under 40 whose legal accomplishments belie their age.